Friday, October 5, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall
Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID
Presentations:
Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)
Brian D. VanScoy, B.S.;
Elizabeth A. Lakota, Pharm.D., M.S.;
Sujata M. Bhavnani, Pharm.D., M.S.;
Greg Giesel, B.S.;
Ana I. Carranco, B.S.;
Yu Nagira, M.S.;
Shohei Ouchi, M.S.;
Kenichiro Kondo, Ph.D.;
Paul G. Ambrose, Pharm.D., FIDSA
Phase I study to evaluate the safety and pharmacokinetics (PK) of single and multiple ascending doses (SAD/MAD) of intravenous (IV) minocycline in healthy adult subjects
Oliver A. Cornely, MD;
Dorothee Arenz, MSc;
Olivier Barraud, MD;
Mark Bayliss, PhD;
Vassiliki Dimitriou, Dipl.-Pharm.;
Stefanie Hamacher, MSc;
Andrew M. Lovering, PhD;
Alasdair MacGowan, MD;
Sue K. Cammarata, MD;
Karen Fusaro, BA;
David C. Griffith, BA;
Elizabeth Morgan, BS;
Jeffery S. Loutit, MBChB
Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model
Christopher M. Rubino, Pharm.D.;
Lukas Stulik, MSc;
Harald Rouha, PhD;
Zehra Visram, PhD;
Adriana Badarau, PhD;
Scott A. Van Wart, Ph.D., M.S.;
Paul G. Ambrose, Pharm.D., FIDSA;
Matthew M. Goodwin, Pharm.D., MBA;
Eszter Nagy, MD, PhD
Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)
Alexander J. Lepak, M.D.;
Miao Zhao, MS, PhD;
Qingmei Liu, MS;
Ping Wang, MS;
Yanli Wang, MS;
Justin C. Bader, Pharm.D., MBA;
Paul G. Ambrose, Pharm.D., FIDSA;
David R. Andes, M.D., FIDSA
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
Elizabeth A. Lakota, Pharm.D., M.S.;
Harish Ganesan, M.S.;
Shawn Flanagan, PhD;
Voon Ong, Ph.D.;
Taylor Sandison, MD, MPH;
Sujata M. Bhavnani, Pharm.D., M.S.;
Christopher M. Rubino, Pharm.D.;
Paul G. Ambrose, Pharm.D., FIDSA
Vancomycin Area under the Curve (AUC) to Predict Nephrotoxicity: A systematic Review and Meta-analysis of observational studies
Doaa Aljefri, PharmD, MSc;
Sean Avedissian, PharmD;
Nathaniel J. Rhodes, PharmD, MSc, BCPS;
Michael Postelnick, RPh BCPS AQ ID;
Marc H. Scheetz, PharmD, MSc, BCPS AQ-ID
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
Sujata M. Bhavnani, Pharm.D., M.S.;
Jeffrey P. Hammel, M.S., B.S.;
Elizabeth A. Lakota, Pharm.D., M.S.;
Brian D. VanScoy, B.S.;
Yu Nagira, M.S.;
Christopher M. Rubino, Pharm.D.;
Nobuo Sato, Ph.D.;
Tomokazu Koresawa, M.S.;
Kenichiro Kondo, Ph.D.;
Paul G. Ambrose, Pharm.D., FIDSA
A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime
Jiajun Liu, PharmD;
Sean Avedissian, Pharm.D.;
Gwendolyn Pais, PhD;
Medha Joshi, PhD;
Nathaniel J. Rhodes, PharmD, MSc, BCPS;
Marc H. Scheetz, PharmD, MSc, BCPS AQ-ID
Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 months - <18 years by Physiologically Based Pharmacokinetic Modeling
Amit Desai, PhD;
Laura Kovanda, PhD;
Christopher Lademacher, MD;
William Hope, BMBS, FRACP, FRCPA, PhD;
Michael Neely, MD, MSc, FCP;
Peter Bonate, PhD;
Andrea Edginton, PhD
β-lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model
Ana Motos, MSc;
Joseph L. Kuti, PharmD;
Gianluigi Li Bassi, MD, Ph.D.;
Antoni Torres, MD, PhD, FERS;
David P. Nicolau, PharmD, FCCP, FIDSA
Efficacy of Daptomycin Combination with ß-lactams for Daptomycin Resistant Enterococcus faecium Harboring LiaSR Substitutions
Razieh Kebriaei, Ph.D.;
Seth Rice, BSc;
Kavindra Singh, Ph.D.;
Kyle Stamper, BSc;
An Dinh, BS;
Rafael Rios, MSc;
Lorena Diaz, PhD;
Barbara Murray, M.D.;
Jose M. Munita, MD;
Truc T. Tran, PharmD;
Cesar Arias, MD, PhD, FIDSA;
Michael J. Rybak, PharmD, MPH, PhD
Daptomycin Combined with Low Dose Ceftriaxone Prevents the Emergence of Daptomycin Resistance against Streptococcus mitis-oralis Group in an In vitro Model of Simulated Endocardial Vegetations (SEVs)
Razieh Kebriaei, Ph.D.;
Seth Rice, BSc;
Kyle Stamper, BSc;
Cristina Garcia-De-La-Maria, PhD;
Nagendra Mishra, PhD;
Jose M Miro, MD, PhD;
Cesar Arias, MD, PhD, FIDSA;
Truc Tran, PharmD;
Paul Sullam, MD;
Arnold Bayer, MD, FIDSA;
Michael J. Rybak, PharmD, MPH, PhD
A Pharmacokinetic study on CMS and Colistin and its impact on clinical cure and acute kidney injury in critically ill patients with normal renal function from south India
Vidya Menon, MD, FACP;
Sangita Sudhir, PharmD;
Merlin Moni, MD;
Dipu Ts, MD;
Zubair Mohammed, MD;
Sabarish Balachandran, MD;
Sanjeev Singh, DCH, MD, PhD;
Payal Patel, MD, MPH;
Keith S. Kaye, MD, MPH
Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Children in the Pediatric Intensive Care Unit
Sean Avedissian, Pharm.D.;
Nathaniel Rhodes, PharmD, MSc;
Yuna Kim, BS;
Josh Valdez, BS;
John Bradley, MD, FAAP;
Jeniffer Le, Pharm.D., MAS, FCCP, FCSHP, BCPS-ID
Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects
Scott A. Van Wart, Ph.D., M.S.;
Christopher Stevens, M.D.;
Zoltan Magyarics, M.D., Ph.D.;
Steven A. Luperchio, Ph.D., CMPP;
Christopher M. Rubino, Pharm.D.;
Paul G. Ambrose, Pharm.D., FIDSA
Caspofungin and Anidulafungin Behave as Fungistatic Agents Against Candida auris.
Catiana Dudiuk, PhD;
Indira Berrio, MD, MSc;
Laura Theill, PhD;
Soraya Morales-Lopez, PhD;
Soraya Salcedo, MD, MSc;
Jose Rodriguez, MD;
Soledad Gamarra, PhD;
Guillermo Garcia-Effron, PhD
A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies
Lilian Kibathi, PharmD;
Parag Kumar, PharmD;
Michail Lionakis, M.D., Sc.D.;
Amanda Urban, CRNP;
Elise Ferre, PA-C, MPH;
Maryellen McManus, RN, MPH;
Benjamin Colton, PharmD;
Chris Lambros, PhD;
Ruying Lu, BS;
Raphael Mannino, PhD;
Edmund Tramont, MD, FIDSA;
Alexandra F. Freeman, MD
24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury
Sean Avedissian, Pharm.D.;
Jiajun Liu, PharmD;
J Nicholas O'Donnell, PharmD, MSc;
Gwendolyn Pais, PhD;
Leighton Becher, BS;
Medha Joshi, PhD;
Walter Prozialeck, PhD;
Peter Lamar, BS;
Thomas P. Lodise Jr., PharmD, PhD;
Marc H. Scheetz, PharmD, MSc, BCPS AQ-ID
CME Credits: Maximum of 0.00 hours of
AMA PRA Category 1 Credit™
